ITRM
Iterum Therapeutics plcNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-0.19
P/S
4.10
EV/EBITDA
-1.05
DCF Value
$-1.10
FCF Yield
-1246.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
-171.3%
Operating Margin
-5202.8%
Net Margin
-6913.1%
ROE
602.4%
ROA
-82.9%
ROIC
-77.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $390.0K | $-9.0M | $-0.20 |
| Q2 2025 | $0.00 | $-6.5M | $-0.16 |
| Q1 2025 | $0.00 | $-4.9M | $-0.14 |
| Q4 2024 | $0.00 | $-6.6M | $-0.25 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
IE
Exchange
NASDAQ
Beta
3.01
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.